Notably, siRNA was used to downregulate c-FLIP in the HepG2 cells and revealed that the downregulation of c-FLIP in HepG2 cells mimicked the effect of rocaglamide on TRAIL-mediated apoptosis in TRAIL-resistant HCC cells. Here, CFLAR is linked to hepatocellular carcinoma.